AstraZeneca Slapped with Antitrust Lawsuit Over Toprol
Charged once again with violating U.S. competition law, pharmaceutical giant AstraZeneca stands accused of illegally trying to prevent generic versions of its blockbuster heart drug Toprol-XL from entering the marketplace in...To view the full article, register now.
Already a subscriber? Click here to view full article